Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Sarah Macadam, chief executive of Thames Valley Positive Support, expects the A&E testing will lead to an increase in demand ...

HIV patients increasingly have the option to collect and ship a drop of their blood in paper-based devices that absorb the sample and store it for analysis in far-away labs. While this technology ...

The global HIV diagnostics market, valued at US$2.96B in 2024, is forecasted to grow at a 10.3% CAGR, reaching US$3.25B by ...

By analyzing genes encoding B-cell and T-cell receptors, the model could screen for conditions like HIV, type 1 diabetes, and ...

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...